Cargando…
Sulforaphane exposure impairs contractility and mitochondrial function in three-dimensional engineered heart tissue
Sulforaphane (SFN) is a phytochemical compound extracted from cruciferous plants, like broccoli or cauliflower. Its isothiocyanate group renders SFN reactive, thus allowing post-translational modification of cellular proteins to regulate their function with the potential for biological and therapeut...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8056268/ https://www.ncbi.nlm.nih.gov/pubmed/33831709 http://dx.doi.org/10.1016/j.redox.2021.101951 |
_version_ | 1783680617092743168 |
---|---|
author | Rhoden, Alexandra Friedrich, Felix W. Brandt, Theresa Raabe, Janice Schweizer, Michaela Meisterknecht, Jana Wittig, Ilka Ulmer, Bärbel M. Klampe, Birgit Uebeler, June Piasecki, Angelika Lorenz, Kristina Eschenhagen, Thomas Hansen, Arne Cuello, Friederike |
author_facet | Rhoden, Alexandra Friedrich, Felix W. Brandt, Theresa Raabe, Janice Schweizer, Michaela Meisterknecht, Jana Wittig, Ilka Ulmer, Bärbel M. Klampe, Birgit Uebeler, June Piasecki, Angelika Lorenz, Kristina Eschenhagen, Thomas Hansen, Arne Cuello, Friederike |
author_sort | Rhoden, Alexandra |
collection | PubMed |
description | Sulforaphane (SFN) is a phytochemical compound extracted from cruciferous plants, like broccoli or cauliflower. Its isothiocyanate group renders SFN reactive, thus allowing post-translational modification of cellular proteins to regulate their function with the potential for biological and therapeutic actions. SFN and stabilized variants recently received regulatory approval for clinical studies in humans for the treatment of neurological disorders and cancer. Potential unwanted side effects of SFN on heart function have not been investigated yet. The present study characterizes the impact of SFN on cardiomyocyte contractile function in cardiac preparations from neonatal rat, adult mouse and human induced-pluripotent stem cell-derived cardiomyocytes. This revealed a SFN-mediated negative inotropic effect, when administered either acutely or chronically, with an impairment of the Frank-Starling response to stretch activation. A direct effect of SFN on myofilament function was excluded in chemically permeabilized mouse trabeculae. However, SFN pretreatment increased lactate formation and enhanced the mitochondrial production of reactive oxygen species accompanied by a significant reduction in the mitochondrial membrane potential. Transmission electron microscopy revealed disturbed sarcomeric organization and inflated mitochondria with whorled membrane shape in response to SFN exposure. Interestingly, administration of the alternative energy source l-glutamine to the medium that bypasses the uptake route of pyruvate into the mitochondrial tricarboxylic acid cycle improved force development in SFN-treated EHTs, suggesting indeed mitochondrial dysfunction as a contributor of SFN-mediated contractile dysfunction. Taken together, the data from the present study suggest that SFN might impact negatively on cardiac contractility in patients with cardiovascular co-morbidities undergoing SFN supplementation therapy. Therefore, cardiac function should be monitored regularly to avoid the onset of cardiotoxic side effects. |
format | Online Article Text |
id | pubmed-8056268 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-80562682021-04-23 Sulforaphane exposure impairs contractility and mitochondrial function in three-dimensional engineered heart tissue Rhoden, Alexandra Friedrich, Felix W. Brandt, Theresa Raabe, Janice Schweizer, Michaela Meisterknecht, Jana Wittig, Ilka Ulmer, Bärbel M. Klampe, Birgit Uebeler, June Piasecki, Angelika Lorenz, Kristina Eschenhagen, Thomas Hansen, Arne Cuello, Friederike Redox Biol Research Paper Sulforaphane (SFN) is a phytochemical compound extracted from cruciferous plants, like broccoli or cauliflower. Its isothiocyanate group renders SFN reactive, thus allowing post-translational modification of cellular proteins to regulate their function with the potential for biological and therapeutic actions. SFN and stabilized variants recently received regulatory approval for clinical studies in humans for the treatment of neurological disorders and cancer. Potential unwanted side effects of SFN on heart function have not been investigated yet. The present study characterizes the impact of SFN on cardiomyocyte contractile function in cardiac preparations from neonatal rat, adult mouse and human induced-pluripotent stem cell-derived cardiomyocytes. This revealed a SFN-mediated negative inotropic effect, when administered either acutely or chronically, with an impairment of the Frank-Starling response to stretch activation. A direct effect of SFN on myofilament function was excluded in chemically permeabilized mouse trabeculae. However, SFN pretreatment increased lactate formation and enhanced the mitochondrial production of reactive oxygen species accompanied by a significant reduction in the mitochondrial membrane potential. Transmission electron microscopy revealed disturbed sarcomeric organization and inflated mitochondria with whorled membrane shape in response to SFN exposure. Interestingly, administration of the alternative energy source l-glutamine to the medium that bypasses the uptake route of pyruvate into the mitochondrial tricarboxylic acid cycle improved force development in SFN-treated EHTs, suggesting indeed mitochondrial dysfunction as a contributor of SFN-mediated contractile dysfunction. Taken together, the data from the present study suggest that SFN might impact negatively on cardiac contractility in patients with cardiovascular co-morbidities undergoing SFN supplementation therapy. Therefore, cardiac function should be monitored regularly to avoid the onset of cardiotoxic side effects. Elsevier 2021-03-31 /pmc/articles/PMC8056268/ /pubmed/33831709 http://dx.doi.org/10.1016/j.redox.2021.101951 Text en © 2021 The Author(s) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Research Paper Rhoden, Alexandra Friedrich, Felix W. Brandt, Theresa Raabe, Janice Schweizer, Michaela Meisterknecht, Jana Wittig, Ilka Ulmer, Bärbel M. Klampe, Birgit Uebeler, June Piasecki, Angelika Lorenz, Kristina Eschenhagen, Thomas Hansen, Arne Cuello, Friederike Sulforaphane exposure impairs contractility and mitochondrial function in three-dimensional engineered heart tissue |
title | Sulforaphane exposure impairs contractility and mitochondrial function in three-dimensional engineered heart tissue |
title_full | Sulforaphane exposure impairs contractility and mitochondrial function in three-dimensional engineered heart tissue |
title_fullStr | Sulforaphane exposure impairs contractility and mitochondrial function in three-dimensional engineered heart tissue |
title_full_unstemmed | Sulforaphane exposure impairs contractility and mitochondrial function in three-dimensional engineered heart tissue |
title_short | Sulforaphane exposure impairs contractility and mitochondrial function in three-dimensional engineered heart tissue |
title_sort | sulforaphane exposure impairs contractility and mitochondrial function in three-dimensional engineered heart tissue |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8056268/ https://www.ncbi.nlm.nih.gov/pubmed/33831709 http://dx.doi.org/10.1016/j.redox.2021.101951 |
work_keys_str_mv | AT rhodenalexandra sulforaphaneexposureimpairscontractilityandmitochondrialfunctioninthreedimensionalengineeredhearttissue AT friedrichfelixw sulforaphaneexposureimpairscontractilityandmitochondrialfunctioninthreedimensionalengineeredhearttissue AT brandttheresa sulforaphaneexposureimpairscontractilityandmitochondrialfunctioninthreedimensionalengineeredhearttissue AT raabejanice sulforaphaneexposureimpairscontractilityandmitochondrialfunctioninthreedimensionalengineeredhearttissue AT schweizermichaela sulforaphaneexposureimpairscontractilityandmitochondrialfunctioninthreedimensionalengineeredhearttissue AT meisterknechtjana sulforaphaneexposureimpairscontractilityandmitochondrialfunctioninthreedimensionalengineeredhearttissue AT wittigilka sulforaphaneexposureimpairscontractilityandmitochondrialfunctioninthreedimensionalengineeredhearttissue AT ulmerbarbelm sulforaphaneexposureimpairscontractilityandmitochondrialfunctioninthreedimensionalengineeredhearttissue AT klampebirgit sulforaphaneexposureimpairscontractilityandmitochondrialfunctioninthreedimensionalengineeredhearttissue AT uebelerjune sulforaphaneexposureimpairscontractilityandmitochondrialfunctioninthreedimensionalengineeredhearttissue AT piaseckiangelika sulforaphaneexposureimpairscontractilityandmitochondrialfunctioninthreedimensionalengineeredhearttissue AT lorenzkristina sulforaphaneexposureimpairscontractilityandmitochondrialfunctioninthreedimensionalengineeredhearttissue AT eschenhagenthomas sulforaphaneexposureimpairscontractilityandmitochondrialfunctioninthreedimensionalengineeredhearttissue AT hansenarne sulforaphaneexposureimpairscontractilityandmitochondrialfunctioninthreedimensionalengineeredhearttissue AT cuellofriederike sulforaphaneexposureimpairscontractilityandmitochondrialfunctioninthreedimensionalengineeredhearttissue |